A Situational Analysis of Antimicrobial Drug Resistance in Africa: Are we Losing the Battle? by Kimang’a, Andrew Nyerere






A SITUATIONAL ANALYSIS OF ANTIMICROBIAL DRUG 
RESISTANCE IN AFRICA: ARE WE LOSING THE BATTLE? 
Andrew Nyerere Kimang’a  
ABSTRACT 
 
BACKGROUND: The first arrival of a sizable shipment of penicillin at the North African Theatre of 
Operations for USA military use in 1943 was a landmark that turned a new chapter of antibiotic use in 
Africa. Over the past decade the expansion of resources and the technological advances have meant that 
much larger quantities of drugs are available in developing countries than ever before. As a result, many 
more individuals are receiving necessary treatment or therapy than just ten years ago. This very welcome 
event is accompanied by the terrible irony that increases in drug availability and use can promote drug 
resistance and render the same life-saving drugs ineffective. 
METHODS: The study focused on bacterial pathogens. One hundred and three relevant literatures were 
identified from the PubMed online database. The coverage included research articles concerning 
antimicrobial resistance involving subjects of an African country.  
RESULTS: Resistant bacteria are on a war path and evidently have acquired an edge over us. Our 
actions are evidently fuelling the resistance. The indiscriminate use of antibiotics in humans and 
livestock, wrong and substandard prescriptions by unqualified ‘medical personnel’ together with poor 
diagnosis or lack of it are all adding fuel to the already fired train of resistant microbes.  
CONCLUSION: To win the war and turn tables as we did with the discovery of penicillin and other 
antimicrobials in the 1940s, then we must all act now. Antimicrobial stewardship programs-Education, 
training of laboratory personnel and investment in laboratory infrastructure development are desirable 
in these situations 
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INTRODUCTION                                                                                                  
 
The discovery of penicillin by Alexander Fleming 
in 1928 (1) and the subsequent administration of 
its first dose in clinical practice in 1941 (2, 3, 4, 5, 
6) marked a landscape shift in patient care. The 
success of antimicrobials against disease-causing 
microbes is among modern medicine’s greatest 
achievements (7). After more than 70 years of 
widespread use, however, many antimicrobials are 
not as effective as they used to be.  The mass 
production of penicillin near the end of the Second 
World War (8) ushered in the era of modern 
antibiotics, causing a paradigm shift in the way we 
view pathogenic bacterial infection.  
The first arrival of a sizable shipment of 
penicillin at the North African Theatre of 
Operations for USA military use in 1943 (9) was a 
landmark that turned a new chapter of antibiotic 
use in Africa. Over the past decade the expansion 
of resources and the technological advances have 
meant that much larger quantities of drugs are 
available in developing countries than ever before. 
As a result, many more individuals are receiving 
necessary treatment or therapy than just ten years 
ago. This very welcome event is accompanied by 
poor practices that promote drug resistance (10). 
Resistance to common antimicrobials affects 
diseases that have not received dedicated increases 
in funding over the past decade. Examples include 
pathogens such as Shigella and Vibrio cholerae 
and Streptococcus pneumoniae. These diseases are 
major causes of childhood death in Sub-Saharan 
Africa (11).  
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Antibiotics are among the most commonly 
prescribed drugs in hospitals (12). In Africa, 
About 90.1% individuals seek care outside the 
home, of these, 94.7% take medicines and 36.2 % 
receive antibiotics. Of all those who receive 
antibiotics, 31.7 % do not receive a prescription 
from a doctor and about 26.4% obtain antibiotics 
from an informal dispenser (13). Evidently 
antibiotics are widely and inappropriately used in 
Africa resulting to antibiotic resistance. This 
situation impinges on the quality of patient care 
through its associated mortality, morbidity, and 
significant economic consequences (14). Since 
antibiotics are the most commonly prescribed 
drugs in hospitals and their use is one of the 
important factors for the development and spread 
of resistance in the hospitals, an audit of their 
susceptibility patterns is important in 
implementation of rational empirical antibiotic 
strategy. 
 
MATERIALS AND METHODS 
 
The study focused on bacterial pathogens. 
Relevant literature was identified from the 
PubMed online database. Each search was 
performed on only English language articles using 
terms like ‘bacterial resistance’, ‘antibiotic use’, 
‘antimicrobial resistance’ and ‘bacterial 
surveillance’ combined with the different 
countries. Bibliographies of all relevant papers 
were searched to identify further papers. Only 
publications listing original data on bacterial 
resistance in humans were included. The coverage 
included research articles concerning 





The Global Burden of Antibiotic Resistance: 
Worldwide, the prevalence of antimicrobial 
resistance limits the therapeutic options for 
treatment of infections, and increases the social 
benefit from disease prevention (15). 
Antimicrobial resistance contributes to the global 
specter of a post-antimicrobial era in which some 
of the most effective tools in the physician‘s 
armamentarium including antibiotics, anti-
tuberculosis and anti-malarial drugs lose their 
effectiveness (16-23). Greater consumption of 
antibiotics appears to correlate with increases in 
antibiotic resistance (24). This is most clearly 
observable in data from the European Surveillance 
of Antimicrobial Consumption (ESAC) study in 
Europe (25). 
Antibiotic Resistance in Southern Africa: A 
review of the susceptibility profiles of Neisseria 
gonorrhoeae over a 20-year period in the Pretoria 
region (26) best portrays the desperate situation of 
antibiotics in South Africa. Findings show that 
Penicillase-producing Neisseria gonorrhoeae 
strains increased from 4% to 16%, whilst 
chromosomally mediated penicillin-resistant 
strains increased dramatically from 0% to 16% 
from 1984 to 2004. High-level tetracycline-
resistant strains (36%) were detected for the first 
time in 2004. Ciprofloxacin resistance emerged at 
7% in the same year. Additionally, Methicillin-
resistant (80%) S. aureus (MRSA) continues to be 
a problem for clinicians (27). Up-regulated 
resistance to many first and second line antibiotics 
in K. pneumoniae and S pneumoniae isolates has 
been documented as well (28, 29). 
In Zimbabwe, there is high resistance to 
Ampicillin (84.5%) and Cotrimoxazole (68.5%) 
among the Gram negative bacilli (30). Gram 
positive cocci show resistance to Nalidixic acid 
(81%) and Cotrimoxazole (69%) with E. coli 
showing as high as 84% resistance to ampicillin 
and 68% to Cotrimoxazole. Over 90% of isolates 
are resistant to Trimethoprim/Sulfamethoxazole 
and 16% are resistant to Tetracycline (31).  
In Mozambique and Angola, increasing 
resistance to Ampicillin, Streptomycin, 
Spectinomycin, Trimethoprime-Sulfisoxazole, 
Kanamycin, Chloramphenicol, Tetracycline and 
Gentamycin has been observed (32-35). In 
patients with no history of prior tuberculosis 
treatment, the multidrug resistance rate is 3.4% 
and resistance to isoniazid and Streptomycin (HS) 
is 5.2% (33). Drug resistance is significantly more 
common among those with a history of prior 
treatment.  
Antibiotic Resistance in East Africa: In Kenya, 
the bacterial infections that contribute most to 
human disease are often those in which resistance 
is most evident (36). Antibiotic resistance patterns 
are reportedly up-regulated in persons living with 
HIV/AIDS (37). Evidently, prolonged exposure to 
antibiotics makes these individuals harbor strains 
that are significantly more resistant to antibiotics. 




In other studies, 71% Staphylococcus aureus 
isolates from Kenya have demonstrated multiple 
drug resistance (38). Elsewhere in Kenya, isolates 
from areas mainly populated by the Maasai 
community majority of who practice traditional 
medicine were characterized (39). Overall 
antibiotic resistance levels was found to be much 
lower than those reported from the rest of Kenya, 
possibly due to the lower levels of exposure and 
usage of antimicrobials among the Maasai 
community. 
In Uganda, resistance to Ampicillin, 
Amoxycillin and Chloramphenicol has been 
documented (40). Staphylococcus aureus 
Pseudomonas aeruginosa, Proteus mirabilis are 
reportedly multidrug resistant. In western Uganda, 
most isolates are resistant to the most commonly 
prescribed antimicrobials (41, 42). Resistance in 
surgical inpatients is significantly higher than 
outpatients (43).  
In Ethiopia, the situation is much dire. 
Gonococcal strains have been found to be 
multidrug resistant (44). Elevated resistance 
among gastrointestinal pathogens (45) as well as 
increased and multiple resistance rates to 
Erythromycin (89.4%), Amoxicillin (86.0%) and 
Tetracycline (72.6%) have been documented in 
isolates from urine, ear discharge, pus swab from 
wounds, and eye discharge (46). Isolates from the 
cerebrospinal fluids (CSF) as well as urinary 
pathogens have demonstrated multidrug resistance 
(47, 48).  
Vlieghe et al. (2008) systematically reviewed 
published literature on bacterial resistance in 
Central African (Cameroon, Chad, Gabon, São 
Tomé e Príncipe, Congo-Brazzaville, Democratic 
Republic of the Congo (DRC) (formerly Zaire), 
the Central African Republic (CAR), Angola and 
Equatorial Guinea) countries (49, 50). Significant 
findings included multidrug resistance in Shigella 
and Salmonella spp. and the emergence of 
Meticillin-resistant Staphylococcus aureus, high-
level Penicillin-resistant Streptococcus 
pneumoniae and extended-spectrum beta-
lactamases among Gram-negative pathogens (50). 
Clearly, Central African region shares the 
worldwide trend of increasing antimicrobial 
resistance.  
Antibiotic Resistance in West and Northern 
Africa: In Egypt, studies have reported Penicillin 
resistant S. pneumonia (51-57). One of the initial 
studies revealed a low percentage of antimicrobial 
resistance (54). An increase in penicillin resistance 
was recorded in a later study where, 0.8% 
resistance was detected (52). Other studies in 
Egypt reveal an increase in resistance to most 
clinical isolates (55, 58, and 59). High rates of 
multidrug resistance in S. pneumoniae have been 
linked to dispensing of antibiotic which are 
generally available as an over-the-counter 
medication (53, 56).  
Nigerian isolates show high resistance in both 
Gram-positive and Gram-negative isolates (60, 
61). Examination of antimicrobial susceptibility of 
Shigella spp. and Escherichia coli, isolates from 
diarrheal patients in Nigeria (62, 63) indicate that 
over 70% of the Shigella isolates are resistant to 
two or more drugs. During 1990–2000, resistance 
to Ampicillin reportedly  increased from 70% to 
90%, Co-trimoxazole from 77% to 85%, 
Chloramphenicol from 71% to 77%, Streptomycin 
from 71% to 79%, and Nalidixic acid from 0% to 
11.3%.  
Root-cause Analysis of antimicrobial resistance 
in Africa: The emergence of antimicrobial 
resistance is primarily due to excessive and often 
unnecessary use of antibiotics in humans and 
animals (64-66). But in Africa, the situation is 
more complex than simple antimicrobial overuse. 
Increasing antimicrobial resistance in Africa has 
been exacerbated by multiple factors. For instance, 
the human resource problem in the health sector in 
sub-Saharan Africa has reached crisis proportions. 
A complex set of factors has contributed to this 
problem, some exogenous, such as the austere 
fiscal measures introduced by structural 
adjustment, which often result in cutbacks in the 
number of health workers. But endogenous factors 
are also to blame, including misdirected human 
resource and training policies, weak institutions, 
and inappropriate structures (67). Conspicuously, 
there are no adequate laboratory facilities (68-70) 
and enough trained staff (71-74) to isolate 
pathogens and perform sensitivity tests so that 
infectious diseases are treated empirically. This 
leads to the extensive use of antimicrobial drugs 
which have favored the emergence of resistant 
strains. 
National laboratory strategic plans that 
specify the policies that govern laboratories are 
inadequate. Consequently, information about drug 
resistance is not properly communicated to those 





prescribing antimicrobials and no adequate 
guidelines regarding the selection of drugs are 
available (75-80). Additionally, there is no 
adequate documented local retrospective data on 
the benches of health care providers to guide good 
antibiotic stewardship. Compounding this problem 
is the lack of infection control procedures and 
wound management in hospitals, resulting in the 
spread of infectious disease and resistant strains 
particularly from the environment (81-84).  
There are several reports of sub-standard and 
counterfeit antimalarial drugs circulating in the 
markets of developing countries (85). About 15% 
of all drugs in circulation worldwide are believed 
to be counterfeit, with the figures rising to as high 
as 50% in some parts of Africa (86). Safety, 
quality, and efficacy of medicines are the three 
most important criteria used by governments to 
regulate pharmaceuticals (87). Quality of drugs is 
especially important and is one of the earliest to 
come under governments’ scrutiny (88). In 
developing countries, the development of national 
drug policies (89, 90) has been necessary to ensure 
the availability of quality pharmaceutical products. 
However, there are still many difficulties in 
effecting quality assurance measures on 
pharmaceutical products circulating in the market. 
Poor quality  of  drugs  has been  linked to  
counterfeiting  of medicines (91), chemical 
instability especially in tropical climate (92)  and  
poor  quality  control  during manufacturing (93). 
Other unresolved chemotherapeutic dilemmas 
have arisen as a result of the AIDS epidemic.  For 
example, there is inconclusive evidence to support 
or refute the use of Trimethoprime-Sulfisoxazole 
for the prevention of opportunistic infections in 
AIDS patients (94, 95). This leads to overuse of 
antimicrobials in these population and thus 
propagates resistance.  Additionally, HIV 
infection is associated with primary multi-drug 
resistant-tuberculosis (96-98). 
Patient knowledge, attitude and behavior of 
antibiotic usage can define nature of antibiotic 
stewardship. Illiteracy among African populations 
and lack of antibiotic awareness leads individuals 
to seek antibiotics for ailments that are naturally 
self-limiting and or at best caused by other factors 
and not necessarily bacterial pathogens (99, 100). 
As well, there is abuse of antibiotic usage in cattle 
(101) in addition to self-medication with 





Antimicrobial stewardship programs have to be 
developed as a response to these issues. As 
antimicrobial resistance increases and the 
development of new antimicrobial agents declines, 
it is critical that we use antimicrobials that are still 
effective wisely and judiciously. Antimicrobial 
stewardship is a systematic approach to optimizing 
the use of antimicrobials. It is used by healthcare 
institutions to reduce inappropriate antimicrobial 
use, improve patient outcomes and reduce adverse 
consequences of antimicrobial use. 
Education is needed to promote acceptance of 
antimicrobial stewardship programme strategies 
and influence prescribing behavior. Education 
should be provided in conjunction with active 
intervention because passive education alone is 
only marginally effective for modifying 
prescribing behavior. Guidelines and clinical 
practices that are evidence based and take into 
consideration local microbiology and 
antimicrobial resistance patterns may improve 
antimicrobial use. These guidelines and clinical 
practices should be developed with 
multidisciplinary input   to improve the likelihood 
of adherence. 
The systemic acute lack of qualified 
laboratory personnel is a major and severe 
constraint in implementing and scaling up 
antibiotic stewardship. In most developing 
countries, there is a clear correlation between the 
quality of trained staff and proximity to the capital 
city. National reference laboratories that are 
situated in the capital city tend to have more 
qualified staff than do regional or district-level 
laboratories. The severe lack of trained laboratory 
experts at the regional and district levels presents 
an additional layer of challenge in the rapid 
expansion and decentralization of prevention and 
care services to district health centers in areas 
where most of the population resides. To achieve 
rapid scale-up of services, the training of 
laboratory personnel is critical at all levels of the 
laboratory network. 
In many African countries, health facilities 
and laboratories in particular are reportedly faced 
with significant infrastructural challenges. 




Documentary evidence indicates that these 
facilities have minimal physical infrastructure, 
with even the physical building being inadequate 
for the needs of the laboratory. Moreover, 
laboratories, when they exist, are reportedly often 
in a degraded state. Significant investment in 
laboratory infrastructure development is desirable 
in these situations. This requires a concerted effort 
by government and external donors, preferably 
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